Latest Mitral valve Stories

--Researchers Presented Positive Preclinical Data That Set the Stage for Longer-Term Tiara Studies Now Underway and Human Trials Planned for 2013-- --Researchers Also Presented Preliminary Registry Study Results Showing Improved Clinical  Status in Refractory Angina Patients Implanted with Neovasc Reducer(TM)-- TSX Venture Exchange: NVC VANCOUVER, Oct. 23, 2012 /PRNewswire/ - Neovasc Inc. (TSXV: NVC) today announced that its Tiara(TM) transcatheter mitral valve in...

BETHLEHEM, Pa., Oct. 22, 2012 /PRNewswire/ -- Micro Interventional Devices, Inc.(TM) (MID), an emerging cardiovascular medical device company, announced today that the first patient has been treated using its self-sealing, cardiac access and closure technology, Permaseal(TM). The patient is the first to be enrolled in the company's STASIS clinical trial that has commenced in Europe. The first STASIS case was performed by Principal Investigator Professor Dr. med. Rudiger Lange,...

--Neovasc's Tiara(TM) Transcatheter Mitral Valve Selected for Inclusion in "Best" New Device Concepts for 2012 Session-- --Other Presentations Include Tiara Project Update and Neovasc Reducer(TM) Preliminary Registry Results-- TSX Venture Exchange: NVC VANCOUVER, Oct. 18, 2012 /PRNewswire/ - Neovasc Inc. (TSXV: NVC) today announced that researchers will present data on the company's two major development products at the upcoming 24(th) Annual Transcatheter Cardiovascular...

Prosthetics can be enlarged as children grow, reducing need for future replacement surgeries BOSTON, Oct. 3, 2012 /PRNewswire-USNewswire/ -- Surgeons at Boston Children's Hospital have successfully implanted a modified version of an expandable prosthetic heart valve in several children with mitral valve disease. Unlike traditional prosthetic valves that have a fixed diameter, the expandable valve can be enlarged as a child grows, thus potentially avoiding the repeat valve...

TSX Venture Exchange: NVC --Vascular Device Leader LeMaitre to Purchase Rights to Manufacture XenoSure Surgical Patch for US $4.6M-- --Neovasc will Continue to Supply Product During Transition and Will Redirect Freed-Up Manufacturing Capacity to Support Growing Sales to Transcatheter Heart Valve Customers-- --Proceeds from the Sale of Rights Will Help Fund Neovasc's Key Development Projects-- VANCOUVER, Oct. 2, 2012 /PRNewswire/ - Neovasc Inc. (TSXV: NVC) today...

KIRKLAND, Wash., Sept. 28, 2012 /PRNewswire/ --Cardiac Dimensions(®),( )Inc. today announced that it has initiated its commercial efforts in Europe, treating the first patients with its CARILLON® Mitral Contour System® under its Conformite Europeenne (CE) Mark approval. The CARILLON system is a novel, minimally invasive therapy for treating heart patients suffering from functional mitral regurgitation (FMR). An estimated 70 percent of the 20 million people worldwide with heart...

--"Encouraging" Short-Term Data from Innovative Product to Treat Mitral Regurgitation Using Transcatheter Approach-- --Chronic Animal Studies Underway in Preparation for Potential First Human Implantations in 2013-- TSX Venture Exchange: NVC VANCOUVER, Sept. 18, 2012 /PRNewswire/ - Neovasc Inc. (TSXV: NVC) today announced that acute results from preclinical studies of its Tiara(TM )valve for the transcatheter treatment of mitral regurgitation were published in the...

WEST BRIDGEWATER, Mass., July 10, 2012 /PRNewswire/ -- Cardiosolutions, Inc. an early-stage company focused on the development of an innovative percutaneous system to treat patients with moderate to severe mitral valve regurgitation, today announced it has received a minority investment from Sorin Group (Reuters Code: SORN.MI), a global medical device company and an international leader in the treatment of cardiovascular disease. Cardiosolutions' technology consists of a...

WEST BRIDGEWATER, Mass., June 13, 2012 /PRNewswire/ -- Cardiosolutions Inc., an emerging leader in structural heart solutions for valvular heart disease, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Dexterity(TM) Steerable Introducer, a next generation structural heart access introducer and delivery conduit. The Dexterity(TM) Steerable Introducer is designed to provide physicians straightforward and...

MISGAV, Israel, June 4, 2012 /PRNewswire/ -- MitrAssist Medical Ltd., a developer of minimally invasive products for treating heart disease, announced today that it received ISO 13485:2003 Certification for the design and development of implantable heart valve prostheses. Today's standard treatment for mitral valve regurgitation (MR), blood leakage or backflow into the atrium, is open heart surgery. MitrAssist's unique design preserves the ventricular dynamic mode of...